Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
Foresight Mental Health is a technology-enabled company focused on providing comprehensive psychiatry and therapy services. It employs a team of psychiatrists, therapists, and psychiatric nurse practitioners who deliver treatment directly to patients in its clinics. Foresight aims to transform mental healthcare by integrating advanced technology developed by its software and biomedical engineers with clinical practice. The company offers a wide range of mental health treatments and wellness services, utilizing patient profiles that incorporate scientific research, genetic information, and detailed assessments of symptoms and brain chemistry. This holistic approach is designed to enhance patient outcomes, promoting improved mental health and overall well-being.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
PMI BioPharma Solutions is providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.
Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.
Cohere Health, Inc. is a software-as-a-service company based in Boston, Massachusetts, that focuses on enhancing the healthcare experience for patients, providers, and health plans. Incorporated in 2019, the company aims to improve the quality of care while reducing overall costs and increasing transparency throughout the patient care journey. Cohere Health specializes in intelligent prior authorization services, which are tailored to meet the specific needs of different health plans. By leveraging artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process and facilitates collaboration between physicians and health plans. This approach not only streamlines the utilization management service but also promotes quality care across the entire patient journey.
Developed by spine specialists, the SpineZone Method relieves long-term back and neck injuries without resorting to invasive procedures
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
Developer of veterinary practice management software intended to empower veterinary practice partners to drive improved health and financial outcomes. The company's services include supply chain services, software services and prescription management, intended for the well-being of animals and those who care for them drives to advance the world of veterinary medicine.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
The One Health Company is a social impact company that brings precision medicine, used in humans, to dogs with cancer.
It started by offering dogs with cancer access to cutting edge human clinical trials at no cost. Then, they created FidoCure directly for veterinarians and pet parents to offer treatment options to more dogs across the country. The company built partnerships with the world's top cancer researchers and a network of 111 of the best veterinary hospitals.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Provider of cancer therapy services intended to improve both the safety and efficacy of cytokine immunotherapies for cancer patients. The company's services offer systemic dosing of these immune stimulants that have historically been limited by broad immune activation and toxicity, develops cancer therapies based on tumor-localized immune potentiating agents that boost anti-tumor immune responses, enabling patients to find an instant treatment for cancer without any surgery.
Foresight Mental Health is a technology-enabled company focused on providing comprehensive psychiatry and therapy services. It employs a team of psychiatrists, therapists, and psychiatric nurse practitioners who deliver treatment directly to patients in its clinics. Foresight aims to transform mental healthcare by integrating advanced technology developed by its software and biomedical engineers with clinical practice. The company offers a wide range of mental health treatments and wellness services, utilizing patient profiles that incorporate scientific research, genetic information, and detailed assessments of symptoms and brain chemistry. This holistic approach is designed to enhance patient outcomes, promoting improved mental health and overall well-being.
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.
Montis Biosciences is a biotechnology company based in Meise, Belgium, focused on developing immune-oncology therapeutics aimed at addressing the relationship between vascular dysfunction and immune suppression in the treatment of solid tumors. Founded in 2020, the company utilizes a target screening and assay platform to identify and develop therapeutic targets that modify the interactions between tumor endothelial cells and perivascular macrophages.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Manufacturer of low-cost and portable breathing devices designed to reduce patient fatalities in resource-limited settings. The company's devices are simple to operate, portable, wirelessly monitored products that can provide continuous ventilation to patients, enabling medical practitioners to minimize the deaths of patients.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
McInnis Law is a law firm based in New York City, established in 1999. The firm specializes in various areas of legal practice, including false claims acts, Medicare billing fraud, pharmaceutical fraud, whistleblower retaliation, and healthcare fraud. Additionally, McInnis Law addresses issues related to ambulance billing fraud, defense contracting fraud, tax matters, customs duty, and anti-money laundering violations. Its comprehensive legal services cater to a diverse clientele, ensuring robust representation and advocacy in complex legal cases.
Private Equity Round in 2019
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Africa Healthcare Network (AHN) has pioneered the first dialysis chain in Sub-Saharan Africa, aimed at delivering affordable, high-quality dialysis services for patients suffering from Acute Kidney Injury and End-Stage Renal Disease. In a region where existing facilities are limited and often charge exorbitant fees, AHN addresses the critical shortage of accessible dialysis care. The organization leverages its technical expertise and practical experience to establish well-equipped centers, while also focusing on training healthcare professionals to enhance service delivery. As Chronic Kidney Disease and related health issues rise due to urbanization and lifestyle changes, AHN's model prioritizes operational efficiency and cost-effective sourcing of medical supplies, thereby reducing treatment costs for patients. Operating in Rwanda, Tanzania, and Kenya, AHN is committed to increasing access to life-saving dialysis care, ultimately improving patient outcomes while ensuring financial sustainability.
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.
Candesant Biomedical develops innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and headquartered in San Francisco, California, the company focuses on a proprietary medical device known as CDX-101. This non-invasive technology utilizes water-activated principles to deliver targeted energy to active sweat glands, effectively inactivating them without discomfort for patients. By controlling the interaction between alkali metals and water, Candesant's device aims to reduce excessive sweating and inhibit bacterial growth, providing a significant improvement in quality of life for individuals affected by this condition.
Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions aimed at enhancing patient outcomes during surgical procedures. Founded in 2011 and headquartered in Los Altos, California, Gauss has developed a vision-based platform that accurately measures surgical blood loss using advanced algorithms and artificial intelligence. Its flagship product, Triton, includes various models tailored for different medical settings, such as Triton OR for operating rooms and Triton L&D for labor and delivery. These devices assist healthcare professionals in early recognition of hemorrhage, provide objective metrics for blood loss, and inform transfusion decisions, ultimately improving patient safety and care quality. Gauss Surgical primarily serves the healthcare sector in the United States.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.
OM1, Inc. is a digital health company that develops a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform supports hospitals and health systems in meeting requirements for patient-reported and clinical outcomes, particularly in value-based care programs and bundle payments. By leveraging advanced analytics, the platform provides predictive and prescriptive insights that help mitigate risks and reduce costs while demonstrating outcomes to various stakeholders. OM1's technology synthesizes and enriches clinical data to offer AI-driven insights that enhance clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014 and based in Boston, Massachusetts, OM1 was previously known as Better Outcomes Corporation.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Nomad Health, Inc. operates an online marketplace that connects healthcare professionals with freelance and permanent job opportunities in the United States. Founded in 2015 and based in New York, the platform allows doctors and nurses to search for positions by various criteria, including location and pay rate. By streamlining the healthcare staffing process, Nomad Health aims to simplify job searches for medical professionals and facilitate the hiring needs of healthcare facilities. This modern technology platform addresses the complexities of traditional healthcare staffing, promoting efficiency and accessibility in the job market.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.
Suono Bio, Inc. is focused on developing a novel platform technology for the rapid and localized delivery of therapeutic products, specifically targeting the gastrointestinal (GI) tract. Incorporated in 2016 and based in Medford, Massachusetts, the company aims to facilitate the administration of small molecules, proteins, vaccines, and nucleic acids without the need for encapsulation. Preclinical studies have shown the platform's effectiveness in delivering various therapeutics both locally and systemically, which supports its potential for treating inflammatory-mediated diseases. This innovative approach may offer significant advancements in therapeutic delivery, enhancing patient recovery from gastrointestinal conditions.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Africa Healthcare Network (AHN) has pioneered the first dialysis chain in Sub-Saharan Africa, aimed at delivering affordable, high-quality dialysis services for patients suffering from Acute Kidney Injury and End-Stage Renal Disease. In a region where existing facilities are limited and often charge exorbitant fees, AHN addresses the critical shortage of accessible dialysis care. The organization leverages its technical expertise and practical experience to establish well-equipped centers, while also focusing on training healthcare professionals to enhance service delivery. As Chronic Kidney Disease and related health issues rise due to urbanization and lifestyle changes, AHN's model prioritizes operational efficiency and cost-effective sourcing of medical supplies, thereby reducing treatment costs for patients. Operating in Rwanda, Tanzania, and Kenya, AHN is committed to increasing access to life-saving dialysis care, ultimately improving patient outcomes while ensuring financial sustainability.
Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
Arsia Therapeutics’ mission is to improve access to these life-saving drugs, make them more patient-friendly, and reduce healthcare costs by enabling subcutaneous delivery in non-hospital settings. Biopharmaceuticals are much larger and more fragile than traditional small-molecule drugs. Due to their size, large doses of biologics are often required; and because of their fragility, these drugs must be administered by injection instead of orally. Biologics become unstable and extremely viscous at the high concentrations required for traditional low-volume injections. Consequently, they are frequently administered as high-volume, slow intravenous infusions in a hospital setting. From a patient perspective, receiving treatment via subcutaneous administration can be preferable to intravenous infusion. Subcutaneous administration removes the need for invasive IV ports. Administration at home eliminates time-intensive and expensive hospital visits. Achieving high doses of biologics in a volume suitable for subcutaneous administration presents significant formulation challenges. The major limiting factor is viscosity, which arises when biomolecules are formulated at high concentration. Arsia’s mission is to produce high-concentration biopharmaceutical products with low viscosity, suitable for small-volume subcutaneous injection. Our proprietary platform technology reduces the viscosity of biologics through the addition of inactive ingredients (excipients). Because Arsia’s technology works at the formulation stage, the molecular structure of the drug itself is not affected. Arsia’s technology provides i) a formulation solution for new products in development that have viscosity challenges, ii) a life-cycle management strategy for existing products and iii) a way to differentiate those products from others on the market. For more information on partnering with Arsia, please contact us.
First Opinion, Inc. is a healthcare technology company based in San Francisco, California, founded in 2013. It has developed a smartphone application that connects mothers with healthcare professionals, specifically doctors who are also mothers, through a messaging platform. This service addresses a range of topics including illness, injury, pregnancy, child development, nutrition, lactation, and sleep training. The application allows users to receive immediate responses to their health-related inquiries, available 24 hours a day. While users can ask questions for free, there is an option to upgrade for additional treatment services if needed.
Novaerus's mission is to improve the business and quality of care through the application of airborne pathogen control technology. Novaerus believe that the preventative approach is the proper path to improved business and quality results in skilled nursing and assisted living facilities. Traditionally, important steps have been taken to clean hands and surfaces. Protocols exist on hand washing, surface cleaning and disinfectant and even isolation used as a tactic to prevent pathogens. When used in conjunction with these traditional methods, the Novaerus technology can go beyond just scrubbing hands and surfaces.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Strata Health leverages technology to achieve dramatic patient flow improvement within health systems. Our clients say they’ve entrusted us with the job of creating patient flow solutions that achieve real and dramatic benefits for patients, their families and the world’s devoted front line caregivers. Operational in Canada and the UK, Strata Health is a privately held Canadian corporation. It is comprised of professionals with empathy for those who need care and intense respect for those who devote themselves to caring for others.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Suneva Medical, Inc. is a medical technology company that develops, manufactures, and commercializes innovative aesthetic products for the dermatology, plastic, and cosmetic surgery markets. Based in San Diego, California, the company offers a range of products, including Bellafill, a unique dermal filler recognized for its long-term safety and efficacy, specifically approved for the correction of facial acne scars and moderate to severe nasolabial folds. Additionally, Suneva Medical provides Puregraft, which enhances fat graft retention, and Suneva Medical HD platelet-rich plasma, facilitating optimal platelet concentrate processing. The company also markets Silhouette InstaLift sutures for cosmetic facial procedures. With a focus on high patient satisfaction and distinct product offerings, Suneva Medical aims to meet the needs of both physicians and patients in the aesthetic market.
Suneva Medical, Inc. is a medical technology company that develops, manufactures, and commercializes innovative aesthetic products for the dermatology, plastic, and cosmetic surgery markets. Based in San Diego, California, the company offers a range of products, including Bellafill, a unique dermal filler recognized for its long-term safety and efficacy, specifically approved for the correction of facial acne scars and moderate to severe nasolabial folds. Additionally, Suneva Medical provides Puregraft, which enhances fat graft retention, and Suneva Medical HD platelet-rich plasma, facilitating optimal platelet concentrate processing. The company also markets Silhouette InstaLift sutures for cosmetic facial procedures. With a focus on high patient satisfaction and distinct product offerings, Suneva Medical aims to meet the needs of both physicians and patients in the aesthetic market.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.
Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Arsenal Medical, Inc. is a platform technology company based in Watertown, Massachusetts, that specializes in developing polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company focuses on creating in-situ forming foams to address acute hemorrhage and other critical medical conditions, including vascular injury and repair. Arsenal Medical's proprietary technologies include its therapeutic foam and AxioCore, a novel nanofiber technology designed to enhance cell integration and tissue regeneration, allowing for the controlled delivery of various biologics and therapeutics. The company is advancing multiple preclinical programs and is supported by venture funding as well as grants from prominent organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.
Phreesia is a privately held company specializing in patient check-in solutions for healthcare organizations. The company offers a wireless touch screen device known as the PhreesiaPad, which automates the patient check-in process by securely collecting personal health information in compliance with HIPAA regulations. This system integrates seamlessly with existing electronic medical records (EMRs) and does not disrupt physician workflows. Phreesia enhances the patient experience by preparing individuals for appointments, providing relevant health education, and allowing them to verify previously recorded information. Additionally, Phreesia's software solutions improve the operational and financial performance of healthcare providers by managing various aspects of patient access, registration, payments, and clinical support. The company is supported by a Medical Advisory Board and has initiated patient care initiatives focused on wellness and disease prevention, having secured $13.25 million in funding to date.
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.